RNXT — RenovoRx, Inc.

RNXT Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q3 2025 revenues were approximately $266,000, contributing to a year-to-date total of about $900,000.
• Research and development expenses amounted to $1.7 million, reflecting ongoing investment in clinical trials.
• Selling, general, and administrative expenses were also $1.7 million, indicating stable operational costs.
• As of September 30, 2025, RenovoRx had over $10 million in cash and cash equivalents, sufficient to support ongoing commercial efforts and clinical trials through 2026.

2. Strategic Updates and Business Highlights:

• RenovoRx is advancing its transarterial microperfusion therapy platform (TAMP) as a new treatment option for solid tumors, particularly pancreatic cancer.
• The company has expanded its commercial footprint from 5 to 14 approved cancer centers for RenovoCath, with 5 centers already using the device and placing repeat orders.
• A new post-marketing registry study has been initiated to gather real-world data on RenovoCath's safety and effectiveness.
• The company is focusing on building a lean, efficient sales and marketing team, including recent hires to enhance commercial efforts.

3. Forward Guidance and Outlook:

• RenovoRx anticipates revenue growth in 2026, supported by a growing network of clinical institutions and physician advocacy.
• The company estimates a potential market opportunity of approximately $400 million annually for RenovoCath, with expectations for expansion into additional tumor types.
• Enrollment for the Phase III TIGER PACT trial is expected to be completed in early 2026, with final data anticipated in 2027.

4. Bad News, Challenges, or Points of Concern:

• The current revenue figures reflect the early stage of commercial launch, and fluctuations in sales are expected due to limited staff and initial patient treatments.
• The company faces the challenge of scaling its operations and increasing market penetration while maintaining fiscal discipline.
• There is a need for ongoing capital management, with potential financing options being explored as the company prepares for broader adoption of its technology.

5. Notable Q&A Insights:

• Management confirmed that the focus remains on the U.S. market for now, citing favorable reimbursement and significant interest domestically.
• The supply chain for RenovoCath is robust, with manufacturing based in the U.S., which has insulated the company from global supply chain issues.
• The sales cycle for hospitals to approve the device can vary widely, from several weeks to several months, but management is optimistic about shortening this timeline with increased regional support.
• The company is seeing positive early adoption metrics, with a strong pipeline of interest from additional hospitals and physicians.

Overall, RenovoRx is positioned for growth with a promising technology and a clear strategy, though it must navigate the challenges of early commercialization and market expansion.